| 上皮性卵巢癌组织uPA、uPAR及PAI-1表达及意义 |
| |
| 引用本文： | 黄翠萍,赵洁,李霞,王蓁.上皮性卵巢癌组织uPA、uPAR及PAI-1表达及意义[J].齐鲁医学杂志,2010,25(3):192-194. |
| |
| 作者姓名： | 黄翠萍 赵洁 李霞 王蓁 |
| |
| 作者单位： | 1. 青岛大学医学院附属医院妇科,山东,青岛,266003
2. 青岛大学医学院附属医院病理科,山东,青岛,266003 |
| |
| 摘 要： | 目的 探讨尿激酶型纤溶酶原激活剂(uPA)、uPA受体(uPAR)及其抑制剂(PAI-1)在上皮性卵巢癌组织中的表达及意义.方法 采用免疫组织化学PV-9000法检测60例上皮性卵巢癌、30例良性卵巢肿瘤及30例正常卵巢组织中uPA、uPAR及PAI-1蛋白表达,并结合临床病理因素进行分析.结果 uPA、uPAR、PAI-1在上皮性卵巢癌中的表达率(75.0%、65.0%、66.7%)明显高于良性肿瘤(40.0%、33.3%、30.0%)及正常组织(30.0%、26.7%、33.3%),差异均有显著性(χ2=11.779～19.510,P<0.05),而良性肿瘤与正常组织比较无明显差异.uPA、uPAR、PAI-1在上皮性卵巢癌组织表达与手术病理分期、组织分级和有无淋巴结转移有关(χ2=8.242～36.906,P<0.05).结论 uPA、uPAR、PAI-1在上皮性卵巢癌组织高表达,可能与卵巢癌发生、发展及浸润有关.
|
| 关 键 词： | 卵巢肿瘤 尿纤溶酶原激活物 纤溶酶原激活物抑制物1 免疫组织化学 |
EXPRESSIONS OF uPA, uPAR AND PAI-1 IN EPITHELIAL OVARIAN CANCER AND THEIR SIGNIFICANCE |
| |
| HUANG CUI-PING,ZHAO JIE,LI XIA,et al.EXPRESSIONS OF uPA, uPAR AND PAI-1 IN EPITHELIAL OVARIAN CANCER AND THEIR SIGNIFICANCE[J].Medical Journal of Qilu,2010,25(3):192-194. |
| |
| Authors: | HUANG CUI-PING ZHAO JIE LI XIA |
| |
| Institution: | HUANG CUI-PING,ZHAO JIE,LI XIA,et al(Department of Obstetrics and Gynecology,The Affiliated Hospital of Qingdao University Medical College,Qingdao 266003,China) |
| |
| Abstract: | Objective To investigate the expressions of urokinase-type plasminogen activator(uPA) and its receptor(uPAR) and plasimnogen activator inhibitors(PAI-1) in epithelial ovarian cancer(EOC) and their significance. Methods Immunohistochemistry was applied to examine the protein expressions of uPA,uPAR and PAI-1 in 60 specimens of EOC and 30 specimens of benign ovarian tumor(BOT) and 30 specimens of normal ovary.The results were analyzed in combined with clinicopathology. Results The positive rates of uPA,uPAR a... |
| |
| Keywords: | ovarian neoplasms urine plasminogen activator plasminogen activator inhibitor 1 immunohistochemistry |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
